Evotec stock weakens after Q2 2026 miss and guidance cut
Published on 08/14/2026 at 08:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec SE (ISIN DE0005664809) stock is trading under pressure in mid-August 2026 after the German drug discovery and development group missed expectations with its second-quarter 2026 results and cut full-year guidance, leaving the Nasdaq-listed American depositary shares close to their 12-month low as of August 13, 2026. Recent coverage of the Q2 2026 release highlights a wider adjusted loss and a revenue shortfall versus analyst estimates, while a separate earnings summary outlines a lower 2026 revenue and EBITDA outlook.
Q2 2026 revenue and earnings miss
The latest quarterly figures show that Evotec generated group revenue of €143.5 million in Q2 2026, down from €171.2 million in Q2 2025, which represents a 16.2 percent year-over-year decline as of the interim report for the three months ended June 30, 2026. An earnings overview published on August 13, 2026 notes that this weakness stems from softer contributions from strategic partnerships and timing effects in milestone and license revenue.
On the profitability line, adjusted group EBITDA in Q2 2026 came in at a loss of €20.8 million, compared with a loss of €5.0 million in the prior-year quarter, marking a deterioration of €15.8 million year-on-year as reported for the same three-month period. The same source explains that the deeper loss reflects lower revenue, reorganization costs and the absence of high-margin milestone income that had supported results in earlier quarters.
In dollar terms for the Nasdaq-listed shares, Evotec reported Q2 2026 earnings per share of -$0.14 as of the quarter ended June 30, 2026, missing the consensus estimate of -$0.05 by $0.09 and underscoring the scale of the earnings disappointment. A same-day analysis of the results points out that this negative surprise contributed to selling pressure in extended trading after the release.
First-half 2026 trends and guidance cut
Looking at the broader first-half picture, Evotec reported group revenue of €300.1 million for the six months ended June 30, 2026, compared with €371.2 million in the first half of 2025, a decline of 19 percent year-on-year according to the interim figures. The same half-year data show adjusted group EBITDA at a loss of €42.7 million versus a loss of €1.9 million in the prior-year period, illustrating how profitability deteriorated more sharply than the top line during the first six months of 2026.
Segment data for Q2 2026 reveal that the Discovery and Preclinical Development business generated revenue of €108.1 million, down 15.8 percent compared with Q2 2025, with adjusted EBITDA of -€14.6 million versus -€2.5 million a year earlier as per the segment reporting for the quarter. In parallel, the Just - Evotec Biologics division recorded Q2 2026 revenue of €35.4 million, down 17.4 percent year-on-year, and adjusted EBITDA of -€6.2 million compared with -€2.5 million in the prior-year quarter, showing that both major segments experienced double-digit revenue declines and deeper losses in the latest quarter.
In response to these weaker trends, Evotec updated its full-year 2026 guidance as of the August 13, 2026 earnings communication. The company now expects 2026 revenue between €570 million and €610 million, down from a previous range of €700 million to €780 million as outlined in the guidance revision. At the same time, the forecast for adjusted group EBITDA has shifted to a loss of between €70 million and €105 million for 2026, compared with a prior outlook that had called for a range of €0 million to €40 million, meaning investors now face a guidance cut of up to €210 million at the top end of revenue and a swing from a potential breakeven to a substantial loss at the EBITDA level.
Analyst consensus and valuation context
The weaker earnings and guidance have also fed into a cautious analyst stance on Evotec as of August 14, 2026. Data compiled from recent research reports indicate that the stock carries a consensus rating of Hold, with an average twelve-month price target of $3.00 for the Nasdaq-listed shares and a forecast range stretching from a low of $2.00 to a high of $4.00 as summarized in a price-target overview updated on August 14, 2026. The latest consensus and price-target snapshot underscores that the current share price near $2.00 leaves some room to upside versus the average target but also reflects skepticism after the guidance cut.
A separate earnings recap dated August 13, 2026 notes that revenue for the quarter, measured in dollars, totaled $161.2 million compared with analyst estimates of $173.87 million, confirming a shortfall versus expectations for the three months ended June 30, 2026. In the same context, Evotec is reported to have a negative net margin of 26.2 percent and a negative return on equity of 24.93 percent for the latest trailing period, indicating that profitability challenges extend beyond a single quarter and affect the overall financial profile.
For investors thinking about valuation, the combination of a share price close to $2.00 and an average target at $3.00 suggests the market is pricing in continued execution risks while still assigning value to Evotec's long-term pipeline and service platform. The roughly one dollar gap between the current level and the consensus target translates to an implied upside potential of close to 50 percent from recent trading levels if the company can stabilize revenues and move adjusted EBITDA closer to break-even in future periods.
Recent share price performance
On the market side, the Nasdaq-listed Evotec American depositary shares under ticker EVO traded down $0.17 to close at $2.02 during regular trading on August 13, 2026, as reported in a same-day price performance overview that also flags trading volume of 24,027 shares versus an average volume of 98,195 shares. The same snapshot places the 12-month low at $1.89, meaning that the $2.02 close sits only $0.13 above that low, and below the 50-day and 200-day moving averages, underlining the stock's weak technical setup as of mid-August 2026.
Evotec's Frankfurt-listed shares under ticker EVT in the Prime Standard segment of the German market are likewise soft. A recent trading summary points out that the Frankfurt shares closed at €3.706 on August 11, 2026, representing a daily gain of 1.37 percent on that session, while separate commentary notes that the stock traded around €3.548 in mid-August 2026, with performance flat over one week but markedly weaker over the prior three months. Together, these figures show that while there has been some short-term stabilization, Evotec's equity value has compressed significantly over a multi-month horizon leading up to the Q2 2026 earnings release.
Market data for the German listing also show a 52-week trading range that has seen the shares move between a lower band near €2.85 and an upper band near €7.98 over the past twelve months, highlighting how far the current level around the mid-€3 zone sits below the highs reached earlier in the year. For investors, the key takeaway is that Evotec stock is now trading in the lower half of its 12-month range and in proximity to major support levels, which may limit downside in the short term but also reflects the market's response to deteriorating fundamentals and lowered guidance.
Project Horizon and operational reshaping
Behind the headline numbers, Evotec is rolling out a transformation effort labeled Project Horizon, which aims to improve operational efficiency and cut costs across the group as of the first half of 2026. An earnings summary dated August 13, 2026 notes that reorganization costs totaled €98.9 million for the six months ended June 30, 2026, tied to the Project Horizon program, and that these charges contributed materially to the widened adjusted EBITDA loss of €42.7 million in the half-year period.
The same half-year commentary highlights that gross margin for the group turned negative at -1.0 percent in the first six months of 2026, compared with a positive margin of 13.6 percent in the prior-year period, reflecting both lower revenue and higher costs in the Just - Evotec Biologics business. At the same time, research and development expenses decreased 30.8 percent to €20.3 million in H1 2026 versus the first half of 2025, signaling more focused capital allocation, while selling, general and administrative expenses fell 11.1 percent to €83.1 million, mainly due to lower consultancy expenses.
Other operating expenses rose sharply to €51.2 million in the first half of 2026, driven by a €42.3 million impairment loss on a Hamburg laboratory building as of the period ended June 30, 2026. This combination of impairment charges and restructuring costs has weighed heavily on profitability metrics, but management argues that the transformation, once completed, should help restore margins in the medium term by aligning capacity and cost structures with demand trends in Evotec's core markets.
Drug discovery and biologics platform
Evotec's business model centers on providing integrated drug discovery and development services to pharmaceutical and biotechnology clients, supplemented by proprietary pipeline projects and platform technologies. The Discovery and Preclinical Development segment offers chemistry, biology, and pharmacology capabilities that help partners identify and optimize new small-molecule candidates, while the Just - Evotec Biologics division supplies design, development, and manufacturing solutions for biologic drugs, including antibodies and other complex modalities.
Within this framework, Evotec has built end-to-end platforms like its integrated drug discovery offerings, which combine high-throughput screening, medicinal chemistry, and computational approaches to accelerate target validation and lead optimization. In biologics, the company uses modular manufacturing setups designed to lower the cost of goods and shorten timelines from early development to clinical supply, a value proposition that has attracted strategic collaborations with larger pharma players in recent years.
The recent financial softness in Just - Evotec Biologics, where Q2 2026 revenue fell 17.4 percent year-on-year to €35.4 million and segment EBITDA losses widened, partly reflects the absence of one-off license deals such as the Sandoz-related transaction that had boosted prior-year figures. As the segment moves beyond that comparison base, investors will be watching whether recurring project revenues and new long-term contracts can offset the loss of such exceptional items and restore positive contributions to group EBITDA.
Shares trade close to lows
As of the close on August 13, 2026, Evotec's Nasdaq-listed EVO shares ended at $2.02 during regular trading, with extended trading showing no significant recovery immediately after the earnings release. That closing price stands only marginally above the 12-month low of $1.89 and firmly below major moving-average reference points, painting a picture of a stock that reflects investor concern over near-term earnings quality and the reduced 2026 guidance.
On the Frankfurt exchange, the latest indicated level around €3.55 for ticker EVT places the German shares in the lower portion of their 12-month trading corridor between roughly €2.85 and €7.98. This means that Evotec's home-market valuation remains depressed compared with earlier in the year, even though the stock did manage a gain of 1.37 percent at €3.706 on August 11, 2026, suggesting that any relief rallies have so far been short-lived in the face of ongoing guidance risks.
For investors, the combination of a guidance cut, widened EBITDA losses, and share prices close to recent lows sets a challenging backdrop. The key question is whether Project Horizon and a more disciplined cost structure can stabilize margins and allow Evotec to convert its strong customer relationships and platform technologies into more consistent earnings over the coming quarters, thereby justifying the analyst consensus that still sees room for upside from current levels.
